Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tamibarotene by Syros Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Tamibarotene is under clinical development by Syros Pharmaceuticals and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Tamibarotene by Syros Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Tamibarotene is under clinical development by Syros Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
SY-5609 by Syros Pharmaceuticals for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Tamibarotene by Syros Pharmaceuticals for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Tamibarotene is under clinical development by Syros Pharmaceuticals and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
SY-5609 by Syros Pharmaceuticals for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
SY-5609 by Syros Pharmaceuticals for Solid Tumor: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
SY-5609 by Syros Pharmaceuticals for Metastatic Pancreatic Cancer: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData,...
SY-5609 by Syros Pharmaceuticals for Small-Cell Lung Cancer: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...
SY-5609 by Syros Pharmaceuticals for Colorectal Cancer: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
SY-5609 by Syros Pharmaceuticals for Ovarian Cancer: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
SY-5609 by Syros Pharmaceuticals for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
SY-5609 by Syros Pharmaceuticals for Metastatic Breast Cancer: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Metastatic Breast Cancer. According to GlobalData,...